Bill Rastetter
InvestorAdvisor at Illumina Ventures
Find your path to Bill
45 people in our graph share verified history with Bill — schools, employers, funds. One of them is your warm intro.
Mark MullaneyunlockedBill: together at Illumina Ventures
×11Bill: together at Illumina Ventures
About
A biotechnology investor and industry veteran, Bill Rastetter served on Illumina's board for 17 years, including a decade as chairman, and holds board roles at companies including GRAIL, Neurocrine Biosciences, and Fate Therapeutics. He co-founded and chaired Receptos (sold to Celgene in 2015), led the merger forming Biogen Idec, co-invented the cancer therapy Rituxan at Idec Pharmaceuticals, and holds a PhD in Chemistry from Harvard.
Colleagues at Illumina Ventures
Abhijit 'Ron' Mazumder, Ph.D.
Partner at Illumina Ventures
Abhijit "Ron" Mazumder
Partner at Illumina Ventures
Alexis Yongmei Ji
Partner at Illumina Ventures
Bill Rastetter, Ph.D.
Advisor at Illumina Ventures
Charles Lin
Principal at Illumina Ventures
Charles White
Senior Associate at Illumina Ventures
Charles White, Ph.D.
Principal at Illumina Ventures
David C. Duffy, Ph.D.
Entrepreneur in Residence at Illumina Ventures
Frequently asked questions
- Who is Bill Rastetter?
- A biotechnology investor and industry veteran, Bill Rastetter served on Illumina's board for 17 years, including a decade as chairman, and holds board roles at companies including GRAIL, Neurocrine Biosciences, and Fate Therapeutics. He co-founded and chaired Receptos (sold to Celgene in 2015), led the merger forming Biogen Idec, co-invented the cancer therapy Rituxan at Idec Pharmaceuticals, and holds a PhD in Chemistry from Harvard.
- Where does Bill Rastetter work?
- Bill Rastetter is Advisor at Illumina Ventures.